Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

June 1, 2013

Primary Completion Date

August 30, 2015

Study Completion Date

December 30, 2015

Conditions
CancerPain
Interventions
DRUG

Oxycodone/Naloxone

DRUG

Oxycodone

Trial Locations (28)

100005

Beijing Hospital, Beijing

100071

307th hospital of Chinese People's medical sciences, Beijing

100142

Beijing Cancer Hospital, Beijing

100191

Peking University Third Hospital, Beijing

100700

General Hospital of Beijing Military, Beijing

100730

Pejing Union Medical College Hospital, Beijing

110001

Hebei Medical University Fouth Hospital, Shijiazhuang

The First Hospital of China Medical University, Shenyang

116023

The second affiliated hospital of Dalian Medical university, Dalian

200003

Shanghai Changzheng Hospital, Shanghai

200080

The first people's hospital of shanghai, Shanghai

200233

The sixth hospital of shanghai, Shanghai

210000

Jiangsu Cancer hospital, Nanjing

250013

The central Hospital of Jinan, Jinan

300060

Tianjin Cancer Hospital, Tianjin

310013

The second hospital of Nanjing Medical university, Nanjing

310016

Sir Run Run Shaw Hospital, Hangzhou

350025

Fuzhou General Hospital of Nanjing Military Command of PLA, Fuzhou

430030

Tongji Hospital Tongji Medical College of HUST, Wuhan

430079

Hubei Cancer Hospital, Changsha

453100

The First Affiliated Hospital of Xinxiang Medical University, Xinxiang

510060

Sun yat-sen univercity cancer center, Guangzhou

710032

Tangdu Hospital,Fourth Military Medical University, Xi’an

Unknown

Fujian Medical University Union Hospital, Fuzhou

The First Affiliated Hospital of Xiamen University, Xiamen

Harbin Cancer Hospital, Harbin

Jilin Cancer Hospital, Changchun

Beijing Friendship Hospital, Beijing

All Listed Sponsors
lead

Mundipharma (China) Pharmaceutical Co. Ltd

INDUSTRY

NCT01885182 - Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain | Biotech Hunter | Biotech Hunter